---
schema_version: "secwatch.filing_event.v1"
accession: "0001641172-25-021356"
form_type: "8-K"
ticker: "MIRA"
cik: "0001904286"
company_name: "MIRA PHARMACEUTICALS, INC."
filed_at: "2025-07-29T23:59:59+00:00"
generated_at: "2026-05-17T23:48:44.555972+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# MIRA reports preclinical data: topical Ketamir-2 comparable to injected morphine in pain model

## Summary
- Topical Ketamir-2 nearly eliminated paw licking and markedly reduced paw lifting in both acute (0-10 min) and inflammatory (15-60 min) phases.
- Comparable efficacy to injected morphine across both pain phases; effects consistent across all 5-min intervals.
- Company continues Phase 1 oral Ketamir-2 trial; Phase 2a in neuropathic pain expected later in 2025.
- Topical Ketamir-2 is being developed as potential non-opioid treatment for diabetic neuropathy, osteoarthritis, and other pain conditions.

## SEC filing metadata
- accession: 0001641172-25-021356
- form_type: 8-K
- ticker: MIRA
- cik: 0001904286
- company_name: MIRA PHARMACEUTICALS, INC.
- filed_at: 2025-07-29T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1904286/000164117225021356/0001641172-25-021356-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1904286/000164117225021356/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001641172-25-021356
- JSON: https://secwatch.observer/filing/0001641172-25-021356.json
- Plain text: https://secwatch.observer/filing/0001641172-25-021356.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.